Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224347 · ClinicalTrials.gov registry record
Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)
A clinical trial of Depression and Cancer, sponsored by Anne Murray.
- Active
- Registry status
- 19,114
- Enrollment target
- 20
- Study locations
NCT07224347: Active study of Depression and Cancer, sponsored by Anne Murray.
NCT07224347 is a study of Depression and Cancer that is active but no longer recruiting, run by Anne Murray. The registered enrollment target is 19,114 participants, above the 758-participant average among 679 other Depression trials with a reported enrollment target (2422% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224347, a study of Depression and Cancer, is active but no longer recruiting, sponsored by Anne Murray.
- ACTIVE NOT RECRUITING
- Registry status
- 19,114 participants
- Enrollment target
- 20
- Study locations
Study Summary
ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.
Primary Outcome
These categories of disability are defined, respectively, as a) all-cause mortality, b) the assessment of dementia by DSM-IV criteria or c) the onset of 'a lot of difficulty' or 'inability' to perform independently, any one of 6 Katz ADLs.
Conditions Studied
Study Locations (20)
Georgia
- Morehouse School of Medicine - Atlanta
- Emory/ Atlanta VAMC - Atlanta
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
- LSU Health Sciences- Shreveport - Shreveport
Michigan
- University of Michigan - Ann Arbor
- Wayne State University - Detroit
Minnesota
- HealthPartners Research Institute - Minneapolis
- Phalen Village Clinic - Saint Paul
North Carolina
- Wake Forest University Baptist Medical Center - Greensboro
- The Brody School of Medicine at East Carolina University - Greenville
Pennsylvania
- Einstein Medical Center - Philadelphia
- University of Pittsburgh Health Sciences Research Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- University of Texas Medical Branch - Galveston
Alabama
- The University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19,114 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2026-04-30 |
What the registry record for NCT07224347 still lists
NCT07224347 is an observational study that tracks outcomes without assigning an intervention. Its 19,114 participants enrollment target places it among the larger protocols in the corpus, above the 758-participant average among 679 other Depression trials with a reported enrollment target (2422% higher).
The record links to 8 conditions, with Depression appearing as the primary indexed condition, and to 0 interventions.
NCT07224347 names 20 study sites across 13 states, led by Georgia, Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT07224347 about?
NCT07224347 is a clinical study titled "Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)". ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE...
What is the current status of trial NCT07224347?
This trial is currently active not recruiting. The enrollment target is 19,114 participants. The study started on 2019-07-15. Estimated completion is 2026-04-30.
What conditions does trial NCT07224347 study?
This clinical trial studies the following conditions: Depression, Cancer, Stroke, Dementia, Frailty.
Who is sponsoring clinical trial NCT07224347?
This trial is sponsored by Anne Murray, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224347 being conducted?
This trial has 20 study locations across Alabama, District of Columbia, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224347's enrollment target sits among peer trials
19,114 4th of 679 higher than 676 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT07152249 · 19,480 participants · NA
Advancing Strategies to Optimize the PerIopeRativE Management of PostOperative Nausea and Vomiting (ASPIRE-PONV) Trial
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy